Drug-drug Interactions Between DWC202211 and DWC202212 in Healthy Subjects
NCT ID: NCT05699070
Last Updated: 2023-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
24 participants
INTERVENTIONAL
2023-02-15
2023-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects
NCT06119958
Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects
NCT05574374
Study to Explore Drug-drug Interactions Between DWC20155 and DWC20156 in Healthy Subjects
NCT02704559
Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults
NCT07213310
Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20162 in Healthy Volunteers
NCT02952755
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DWC202211
DWC202211 100mg
DWC202211 for 5 days
Aspirin 100mg
DWC202212
DWC202212 5mg
DWC202212 for 3 days
Rabeprazole 5mg
DWC202211 + DWC202212
DWC202211 100mg + DWC202212 5mg
DWC202211 + DWC202212 for 5 days
Aspirin 100mg, Rabeprazole 5mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DWC202211 100mg
DWC202211 for 5 days
Aspirin 100mg
DWC202212 5mg
DWC202212 for 3 days
Rabeprazole 5mg
DWC202211 100mg + DWC202212 5mg
DWC202211 + DWC202212 for 5 days
Aspirin 100mg, Rabeprazole 5mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects with a body weight ≥ 50.0 kg to ≤ 90.0 kg with a body mass index (BMI) of ≥ 18.0 kg/m2 to ≤ 27.0 kg/m2 at screening
※ BMI (kg/m2) = body weight (kg)/\[height (m)\]2
* Subjects who voluntarily decided to participate in the study and provided written consent to follow precautions after receiving a sufficient explanation on this study and fully understanding the information
* Subjects who are eligible to participate in the study at the discretion of the investigator by physical examination, laboratory tests, and investigator questioning, etc.
19 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daewoong Pharmaceutical Co. LTD.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DW_DWJ1610101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.